Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Research Report 2024

Publication ID:

PB504243360

Publication Date:

April 26, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

Diabetic retinopathy (DR) represents a major cause of visual impairment in developed countries. The ever-growing incidence of DR and its complications necessitates new strategies to screen patients, prevent complications and optimize management. For this reason, DR is a major target of AI-based models, especially those that can be used for large-scale screening. AI models should recognize DR-related alterations, such as haemorrhages, exudates, cotton wool spots and neovascularization; and, starting from fundus images, establish the presence or absence of DR, and grade it according to the conventional DR grading scales.
The global Diabetic Retinopathy (DR) Artificial Intelligence Screening System market was valued at US$ 86.8 million in 2023 and is anticipated to reach US$ 6767 million by 2030, witnessing a CAGR of 84.8% during the forecast period 2024-2030.
Diabetes continues to rise throughout the United States and worldwide. Estimates show that the prevalence of diabetes mellitus will rise to 578 million people (10.2%) by the year 2030 and 700 million people (10.9%) by the year 2045. This increase in the prevalence of diabetes can also lead to a corresponding increase in diabetic complications, including nephropathy, cardiovascular disease, neuropathy, and retinopathy.
This report aims to provide a comprehensive presentation of the global market for Diabetic Retinopathy (DR) Artificial Intelligence Screening System, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetic Retinopathy (DR) Artificial Intelligence Screening System.
The Diabetic Retinopathy (DR) Artificial Intelligence Screening System market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diabetic Retinopathy (DR) Artificial Intelligence Screening System market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diabetic Retinopathy (DR) Artificial Intelligence Screening System companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Airdoc Technology
Digital Diagnostics
Eyenuk
RetinaLyze System
Optomed
Sibionics Technology
Aeye Health
VUNO
Medimaging Integrated Solution
EyRIS (SELENA+)
Vistel
RETINA-AI Health
Acer Medical
Segment by Type
Hardware
Software
Segment by Application
Medical Institutions
Great Health Scene
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diabetic Retinopathy (DR) Artificial Intelligence Screening System company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Hardware
1.2.3 Software
1.3 Market by Application
1.3.1 Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Medical Institutions
1.3.3 Great Health Scene
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Perspective (2019-2030)
2.2 Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Growth Trends by Region
2.2.1 Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Diabetic Retinopathy (DR) Artificial Intelligence Screening System Historic Market Size by Region (2019-2024)
2.2.3 Diabetic Retinopathy (DR) Artificial Intelligence Screening System Forecasted Market Size by Region (2025-2030)
2.3 Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Dynamics
2.3.1 Diabetic Retinopathy (DR) Artificial Intelligence Screening System Industry Trends
2.3.2 Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Drivers
2.3.3 Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Challenges
2.3.4 Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Retinopathy (DR) Artificial Intelligence Screening System Players by Revenue
3.1.1 Global Top Diabetic Retinopathy (DR) Artificial Intelligence Screening System Players by Revenue (2019-2024)
3.1.2 Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Revenue Market Share by Players (2019-2024)
3.2 Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Diabetic Retinopathy (DR) Artificial Intelligence Screening System Revenue
3.4 Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Concentration Ratio
3.4.1 Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Retinopathy (DR) Artificial Intelligence Screening System Revenue in 2023
3.5 Global Key Players of Diabetic Retinopathy (DR) Artificial Intelligence Screening System Head office and Area Served
3.6 Global Key Players of Diabetic Retinopathy (DR) Artificial Intelligence Screening System, Product and Application
3.7 Global Key Players of Diabetic Retinopathy (DR) Artificial Intelligence Screening System, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetic Retinopathy (DR) Artificial Intelligence Screening System Breakdown Data by Type
4.1 Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Historic Market Size by Type (2019-2024)
4.2 Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Forecasted Market Size by Type (2025-2030)
5 Diabetic Retinopathy (DR) Artificial Intelligence Screening System Breakdown Data by Application
5.1 Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Historic Market Size by Application (2019-2024)
5.2 Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size (2019-2030)
6.2 North America Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size by Country (2019-2024)
6.4 North America Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size (2019-2030)
7.2 Europe Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size by Country (2019-2024)
7.4 Europe Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size (2019-2030)
8.2 Asia-Pacific Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size by Region (2019-2024)
8.4 Asia-Pacific Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size (2019-2030)
9.2 Latin America Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size by Country (2019-2024)
9.4 Latin America Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size (2019-2030)
10.2 Middle East & Africa Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size by Country (2019-2024)
10.4 Middle East & Africa Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Airdoc Technology
11.1.1 Airdoc Technology Company Details
11.1.2 Airdoc Technology Business Overview
11.1.3 Airdoc Technology Diabetic Retinopathy (DR) Artificial Intelligence Screening System Introduction
11.1.4 Airdoc Technology Revenue in Diabetic Retinopathy (DR) Artificial Intelligence Screening System Business (2019-2024)
11.1.5 Airdoc Technology Recent Development
11.2 Digital Diagnostics
11.2.1 Digital Diagnostics Company Details
11.2.2 Digital Diagnostics Business Overview
11.2.3 Digital Diagnostics Diabetic Retinopathy (DR) Artificial Intelligence Screening System Introduction
11.2.4 Digital Diagnostics Revenue in Diabetic Retinopathy (DR) Artificial Intelligence Screening System Business (2019-2024)
11.2.5 Digital Diagnostics Recent Development
11.3 Eyenuk
11.3.1 Eyenuk Company Details
11.3.2 Eyenuk Business Overview
11.3.3 Eyenuk Diabetic Retinopathy (DR) Artificial Intelligence Screening System Introduction
11.3.4 Eyenuk Revenue in Diabetic Retinopathy (DR) Artificial Intelligence Screening System Business (2019-2024)
11.3.5 Eyenuk Recent Development
11.4 RetinaLyze System
11.4.1 RetinaLyze System Company Details
11.4.2 RetinaLyze System Business Overview
11.4.3 RetinaLyze System Diabetic Retinopathy (DR) Artificial Intelligence Screening System Introduction
11.4.4 RetinaLyze System Revenue in Diabetic Retinopathy (DR) Artificial Intelligence Screening System Business (2019-2024)
11.4.5 RetinaLyze System Recent Development
11.5 Optomed
11.5.1 Optomed Company Details
11.5.2 Optomed Business Overview
11.5.3 Optomed Diabetic Retinopathy (DR) Artificial Intelligence Screening System Introduction
11.5.4 Optomed Revenue in Diabetic Retinopathy (DR) Artificial Intelligence Screening System Business (2019-2024)
11.5.5 Optomed Recent Development
11.6 Sibionics Technology
11.6.1 Sibionics Technology Company Details
11.6.2 Sibionics Technology Business Overview
11.6.3 Sibionics Technology Diabetic Retinopathy (DR) Artificial Intelligence Screening System Introduction
11.6.4 Sibionics Technology Revenue in Diabetic Retinopathy (DR) Artificial Intelligence Screening System Business (2019-2024)
11.6.5 Sibionics Technology Recent Development
11.7 Aeye Health
11.7.1 Aeye Health Company Details
11.7.2 Aeye Health Business Overview
11.7.3 Aeye Health Diabetic Retinopathy (DR) Artificial Intelligence Screening System Introduction
11.7.4 Aeye Health Revenue in Diabetic Retinopathy (DR) Artificial Intelligence Screening System Business (2019-2024)
11.7.5 Aeye Health Recent Development
11.8 VUNO
11.8.1 VUNO Company Details
11.8.2 VUNO Business Overview
11.8.3 VUNO Diabetic Retinopathy (DR) Artificial Intelligence Screening System Introduction
11.8.4 VUNO Revenue in Diabetic Retinopathy (DR) Artificial Intelligence Screening System Business (2019-2024)
11.8.5 VUNO Recent Development
11.9 Medimaging Integrated Solution
11.9.1 Medimaging Integrated Solution Company Details
11.9.2 Medimaging Integrated Solution Business Overview
11.9.3 Medimaging Integrated Solution Diabetic Retinopathy (DR) Artificial Intelligence Screening System Introduction
11.9.4 Medimaging Integrated Solution Revenue in Diabetic Retinopathy (DR) Artificial Intelligence Screening System Business (2019-2024)
11.9.5 Medimaging Integrated Solution Recent Development
11.10 EyRIS (SELENA+)
11.10.1 EyRIS (SELENA+) Company Details
11.10.2 EyRIS (SELENA+) Business Overview
11.10.3 EyRIS (SELENA+) Diabetic Retinopathy (DR) Artificial Intelligence Screening System Introduction
11.10.4 EyRIS (SELENA+) Revenue in Diabetic Retinopathy (DR) Artificial Intelligence Screening System Business (2019-2024)
11.10.5 EyRIS (SELENA+) Recent Development
11.11 Vistel
11.11.1 Vistel Company Details
11.11.2 Vistel Business Overview
11.11.3 Vistel Diabetic Retinopathy (DR) Artificial Intelligence Screening System Introduction
11.11.4 Vistel Revenue in Diabetic Retinopathy (DR) Artificial Intelligence Screening System Business (2019-2024)
11.11.5 Vistel Recent Development
11.12 RETINA-AI Health
11.12.1 RETINA-AI Health Company Details
11.12.2 RETINA-AI Health Business Overview
11.12.3 RETINA-AI Health Diabetic Retinopathy (DR) Artificial Intelligence Screening System Introduction
11.12.4 RETINA-AI Health Revenue in Diabetic Retinopathy (DR) Artificial Intelligence Screening System Business (2019-2024)
11.12.5 RETINA-AI Health Recent Development
11.13 Acer Medical
11.13.1 Acer Medical Company Details
11.13.2 Acer Medical Business Overview
11.13.3 Acer Medical Diabetic Retinopathy (DR) Artificial Intelligence Screening System Introduction
11.13.4 Acer Medical Revenue in Diabetic Retinopathy (DR) Artificial Intelligence Screening System Business (2019-2024)
11.13.5 Acer Medical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Airdoc Technology
Digital Diagnostics
Eyenuk
RetinaLyze System
Optomed
Sibionics Technology
Aeye Health
VUNO
Medimaging Integrated Solution
EyRIS (SELENA+)
Vistel
RETINA-AI Health
Acer Medical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂